Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198

(2010) Antonio C. Wolff et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

(2010) D. Slamon et al.   CANCER RESEARCH

Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.

(2010) E. Perez et al.   CANCER RESEARCH

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

(2010) Marion Procter et al.   JOURNAL OF CLINICAL ONCOLOGY

Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials

(2010) Stuart D. Russell et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

(2010) John MS Bartlett et al.   LANCET ONCOLOGY

Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial

(2009) Elmar Stickeler et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

(2009) Maureen E. Trudeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

(2009) Christos Christodoulou et al.   ONCOLOGY

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

(2008) D. Rayson et al.   ANNALS OF ONCOLOGY

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

(2007) Alessandra Gennari et al.   JNCI-Journal of the National Cancer Institute